Advanced searches left 3/3

Radiation Therapy - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 12 June 2022

* If you want to update the article please login/register

Exercise Therapy in Radiation Therapy (EXERT)

"To determine the acceptability, feasibility, and safety of an exercise intervention among cancer patients undergoing radiation therapy. " The investigators anticipate that more than half of the patients will comply with the protocol; over 33% of eligible radiation therapy patients who have expressed consent will perform the therapy; and 5% of participants will suffer a musculoskeletal injury with symptoms persisting for at least six weeks or requiring medical attention, while 5% will suffer a musculoskeletal injury with symptoms persisting a week or requiring medical attention. To determine the clinical findings of patients receiving RT+ET, the investigators must determine the medical results of their RT+ET therapy. The idea is that adding ET to RT will improve patient outcomes and physical stability, according to the hypothesis. The investigators' proposal would be to use standardized questionnaires and assessment software: patient reported outcomes will be monitored using Common Terminology Criteria for Adverse Events - Patient Reported Outcomes, which are tablet-based medications used in the clinic; patient reported outcomes would be assessed using Common Terminology Criteria.

Source link: https://clinicaltrials.gov/ct2/show/NCT03905356


Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation Therapy

"Examples of planned research include an investigation into the effects of radiotherapy on peripheral leukocyte phenotype, peripheral blood protein, and metabolism changes as well as measurements of matrix metalloproteinases in urine. OBJECTIVES: This protocol provides a way of gathering blood and urine samples in patients undergoing radiation therapy for a variety of illnesses. ELIGIBILITY: Patients seen in the radiation oncology clinic will be encouraged to donate blood and/or urine before, during, and after their treatment.

Source link: https://clinicaltrials.gov/ct2/show/NCT00027326


Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)

"While on active surveillance, patients with intermediate risk prostate cancer and minimal side effects are at a higher risk of progression. " The benefits of definitive treatment with RT or surgery may not outweigh the risks of monitoring in intermediate-risk prostate cancer patients due to increased morbidity of treatment. While reducing prostate cancer with minimal side effects, IRE can be helpful in treating prostate cancer with minimal side effects, but it does pose a risk of recurrence in patients with nontreated low risk prostate cancer. For those patients with intermediate risk prostate cancer, RTIRE may be a treatment option. Study Completion The participant is said to have completed the investigation if he has completed all phases of the investigation, including the last visit or the last scheduled procedure shown in the Schedule of Assessments, Section 6. 1. Via the NanoKnife System, the prostate area that had been positive for cancer based on the transperineal prostate biopsy will be targeted for removal. The ultrasound grid, which was used during the mapping biopsy, would be oriented using anatomical landmarks and used to determine the location of the positive biopsy cores. The location of the probes will be documented by ultrasound imaging after the introduction of the NanoKnife probes in the prostate and immediately prior to NanoKnife therapy, to reduce muscle contraction that is associated with the use of the NanoKnife System. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT05345444


A Phase 1 Study of Trametinib in Combination With Radiation Therapy for Brain Metastases

"To find the maximally tolerated dose of trametinib in patients with brain metastases that can be used in combination with whole brain radiation therapy in patients with brain metastases. " trametinib in resected brain metastatic lesions can be quantified by high performance liquid chromatography/tandem mass spectrometry, comparing adjacent tissues: brain margin, arachnoid, and cerebrospinal fluid. For brain metastases, it's possible to assess the tolerability and feasibility of the combination of trametinib and radiation therapy in the brain. Evaluation of Objective Response Rate Perception Criteria in Solid Tumors Criteria of combination trametinib and radiation therapy. Patients are randomized to one of two disease cohorts. Patients receive trametinib orally every four weeks for a week. COHORT B: Patients receive trametinib orally for four weeks. Patients undergo whole brain radiation therapy for three weeks a week, beginning in week 2 in week 2. Patients develop trametinib PO QD on days 1-14, which is followed by surgical resection of the tumor.

Source link: https://clinicaltrials.gov/ct2/show/NCT02015117


Pilot Study of Mobile Application Designed to Assist Patients Undergoing Radiation Therapy

"To determine whether current or new features for the mobile application should be given to future patients. " Patients use the oncpatient mobile application throughout the course of radiation therapy, as shown by the following: OUTLINE: Patients use the oncpatient mobile app over the course of radiation therapy. Patients also complete a poll on the last day of radiation therapy. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT05173961


Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II

"To determine if rituximab simultaneously with radiation and maintenance rituximab provides a significant advantage over radiation alone. " ARM I: Patients receive rituximab intravenously over 4-6 hours every week for two weeks and then every 2 weeks for up to four additional doses in the absence of disease progression or unacceptable toxicity. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT01473628


Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

On a multiparametric MRI report/s, "Evaluate the relationship between histopathology findings in comparison to prostate regions that have been shown to be suspicious for harboring tumor burdens. " Demonstration of the dosimetric and radiobiological benefits of focal stereotactic body radiation therapy versus whole-gland radiation therapy. Patients undergoing additional MRI scans between the 2nd and 3rd fractionated therapies, at 6 months after the cessation of radiation therapy, and at 12 and 24 months. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT02163317


Quality of Life and Supportive Care Preferences Following Radiation Therapy in Prostate Cancer Survivors

"To develop understanding of the effects of prostate cancer on aspects of psychological stability, physiological distress, and health-related quality of life for males who are receiving radiation therapy. " To determine whether biomarkers of stress, inflammation, and autonomic control could identify or disprove the self-reported measures of mental distress and HRQL of a particular group of prostate cancer patients, please refer to our article.

Source link: https://clinicaltrials.gov/ct2/show/NCT02704377


A Pilot Study of Perfusion CT for Lung Tumors Treated With Stereotactic Ablative Radiation Therapy (SABR)

"To determine the possibility of doing computed tomography perfusion imaging at baseline, 48 hours post-stereotactic ablative radiation therapy, and 2-4 months SABR in patients undergoing SABR for treatment of a lung tumor per standard of care. " Perfusion results will be correlated with tumor control at 1 year post-SABR, with tumor control being the absence of evidence of disease seen at the SABR site one year post-SABR," according to one year post-SABR's surveillance images at 1 year post-SABR.

Source link: https://clinicaltrials.gov/ct2/show/NCT02693080


Smartphone Pain App for Assessing Oral Mucositis Pain in Patients Receiving Head and Neck Radiation Therapy

"OM PAIN APP : The Oral Mucositis PAIN APP is a smartphone app that was intended to enable patients to specify in pain severity by using a graphic analogy of the 0-10 scale. " The App is designed with an alarm to alert the patient to track pain severity at set intervals daily and spontaneous patient input. Any patient's smartphone data can be backed up wirelessly to a central server where the results can be analyzed remotely or displayed on the device. A summary measure that incorporates serial assessments of a patient's pain throughout the study's period of study shows that the software is capable of producing a time-weighted measure of pain, total area under the pain cure, and a time-weighted measure of pain. Subjects will be shown a preprogrammed alarm four times a day from their smartphones, causing them to directly experience OM pain levels on the device. Patients may submit as many pain entries as they desire, above the four minimum requirements. Since mucositis symptoms do not begin during radiation therapy, and no longer than week 2 will be used for baseline data. Recording of data will stop four weeks after the completion of radiation therapy, at which time mucositis symptoms typically start to resolve and pain relief signs are absent. Physical fitness will be measured directly with accelerometers to help determine whether decline in physical activity is related to pain severity.

Source link: https://clinicaltrials.gov/ct2/show/NCT02727062

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions